MeSH D009456 - neurofibromatosis 1
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AstraZeneca | Selumetinib | Koselugo | 2025-03-13 | 2020-04-10 | $189 M | Q1/21-Q2/23 |
Clinical Trials
Historical Success Rate
Phase 1
75%9/12
Phase 2
13%5/38
Phase 3
43%3/7
Approved: 2Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use